Artículos de revistas
Ovarian Failure In Sle Patients Using Pulse Cyclophosphamide: Comparison Of Different Regimes
Registro en:
Rheumatology International. , v. 28, n. 6, p. 567 - 571, 2008.
1728172
10.1007/s00296-007-0478-3
2-s2.0-41049115751
Autor
Appenzeller S.
Blatyta P.F.
Costallat L.T.L.
Institución
Resumen
The objective of this study was to determine the frequency and risk factors of early ovarian failure in systemic lupus erythematosus (SLE) women treated with cyclophosphamide (CY). We further tried to determine if there was a reduction of ovarian failure in recent years, due to reduction in the CY dose. We reviewed the charts of all women below 40 years of age who received intravenous CY pulse therapy. In order to be included, the patients must have finished CY treatment before completing 40 years. Patients were divided into two groups: Group A (57 patients), patients who were treated with 0.75 mg/body surface; Group B (50 patients), patients treated with 0.5 mg/body surface. Fifty patients with similar age distribution who never received CY were selected from the database as a control group (Group C). The Chi-square test was applied to compare the categorical variables of the groups and whenever needed, the Fisher's Exact test was used. We observed similar age distribution and disease duration at disease onset between groups. Also, no differences regarding the age at menarche, total prednisone dose, and SLICC-ACR/DI scores were observed at disease onset between the three groups. In group A, ten (17.5%) patients refereed sustained amenorrhea, independently associated with treatment duration (P = 0.001), total intravenous cyclophosphamide (IV-CF) dose (P = 0.02), older age at disease onset (P = 0.04). Seven (12.3%) patients referred transient amenorrhea. Transient amenorrhea was related to CY treatment duration (P = 0.017). In group B, no patient reported sustained amenorrhea and 10 of 50 (20%) patients referred transient amenorrhea, related to CY treatment duration (P = 0.017). The most important risk factors for menstrual abnormalities were duration of treatment and cumulative dose of CY. Lower CY dose reduced the number of premature ovarian failures significantly in this cohort. © 2007 Springer-Verlag. 28 6 567 571 Cervera, R., Khamashtra, M.A., Font, J., Systemic lupus erythematosus: Clinical and immunological patterns of disease expression in a cohort of 1,000 patients (1993) Medicine, 72, pp. 113-124 Balow, J.E., Austin, H.A., Tsokos, G.C., Antonovych, T.T., Steinberg, A.D., Klippel, J.H., NIH conference: Lupus nephritis (1987) Ann Intern Med, 106, pp. 79-94 Neuwelt, C.M., Lacks, S., Kaye, B.R., Ellman, J.B., Borenstein, D.G., Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus (1995) Am J Med, 98, pp. 32-41 Boumpas, D.T., Austin, I.I.I.H.A., Vaughn, E.M., Klippel, J.H., Steinberg, A.D., Yarboro, C.H., Balow, J.E., Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis (1992) Lancet, 340, pp. 741-745 Boumpas, D.T., Barez, S., Klippel, J.H., Balow, J.E., Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus (1990) Ann Intern Med, 112, pp. 674-677 Fukuda, M., Kamiyama, Y., Kawahara, K., Kawamura, K., Mori, T., Honda, M., The favorable effect of cyclophosphamide pulse therapy in the treatment of massive pulmonary hemorrhage in systemic lupus erythematosus (1994) J Pediatr, 153, pp. 167-170 Schroeder, J.O., Euler, H.H., Loffler, H., Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus (1987) Ann Intern Med, 107, pp. 344-346 Valeri, A., Radhakrishnan, J., Estes, D., D'Agati, V., Kopelman, R., Pernis, A., Flis, R., Appel, G.B., Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: A prospective five-year study (1994) Clin Nephrol, 42, pp. 71-78 Austin I.I.I.H.A.́, Klippel, J.H., Balow, J.E., Le Riche, N.G.H., Steinberg, A.D., Plotz, P.H., Decker, J.L., Therapy of lupus nephritis - Controlled trial of prednisone and cytotoxic drugs (1986) N Engl J Med, 314, pp. 614-619 Houssiau, F.A., D'Cruz, D.P., Haga, H.J., Hughes, G.R.V., Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: A preliminary study (1991) Lupus, 1, pp. 31-35 Kumar, R., Biggart, J.D., McEvoy, J., McGeown, M.C., Cyclophosphamide and reproductive function (1972) Lancet, 1, pp. 1212-1214 Martin, F., Lauwerys, B., Lefebvre, C., Devogelaer, J.P., Houssiau, F.A., Side-effects of intravenous cyclophosphamide pulse therapy (1997) Lupus, 6, pp. 254-257 Mok, C.C., Lau, C.S., Wong, R.W.S., Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy (1998) Arthritis Rheum, 41, pp. 831-837 McDermott, E.M., Powell, R.J., Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide (1996) Ann Rheum Dis, 55, pp. 224-229 Langevitz, P., Klein, L., Pras, M., Many, A., The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis (1992) Am J Reprod Immunol, 28, pp. 157-158 Huong, D.L., Amoura, Z., Duhaut, P., Sbai, A., Costedoat, N., Wechsler, B., Piette, J.C., Risk of ovarian failure and fertility after intravenous cyclophosphamide. a study in 84 patients (2002) J Rheumatol, 29, pp. 2571-2576 Warne, G.L., Fairley, K.F., Hobbs, J.B., Martin, F.I.R., Cyclophosphamide induced ovarian failure (1973) N Engl J Med, 289, pp. 1159-1162 Uldall, P.R., Kerr, D.N.S., Tacchi, D., Sterility in cyclophosphamide (1972) Lancet, 1, pp. 693-694 Wang, C.L., Wang, F., Bosco, J.J., Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus (1995) Lupus, 4, pp. 11-14 Boumpas, D.T., Austin H.A.́, Vaughn, E.M., Yarboro, C.H., Klippel, J.H., Balow, J.E., Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy (1993) Ann Intern Med, 119, pp. 366-369 Fogelman, I., The effects of oestrogen deficiency on the skeleton and its prevention (1996) Br J Obstet Gynaecol, 103, pp. 5-9. , 14 Van Der Schoun, Y.T., Van Der Graaf, Y., Steyeberg, E.W., Eijkemans, J.C., Banga, J.D., Age at menopause as a risk factor for cardiovascular mortality (1996) Lancet, 347, pp. 714-718 Tan, E.M., Cohen, A.J., Fries, J.F., The 1982 revised criteria for the classification of systemic lupus erythematosus (1982) Arthritis Rheum, 25, pp. 1271-1277 Bombardier, C., Gladman, D.D., Urowitz, M., Caron, D., Chang, C., Derivation of the SLEDAI: A disease activity index for lupus patients (1992) Arthritis Rheum, 35, pp. 630-640. , The Committee on Prognosis Studies in SLE Gladman, D., Glinzler, E., Goldsmith, C., The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus (1996) Arthritis Rheum, 39, pp. 363-378 Brandt, J.T., Triplett, D.A., Scharer, I., Criteria for the diagnosis of lupus anticoagulant: An update (1995) Thromb Haemost, 74, pp. 1185-1190 Tincani, A., Cyclophosphamide therapy induces ovarian failure in premenopausal women affected by systemic lupus erythematosus (2001) Clin Exp Rheumatol, 19, pp. 490-491 Blumenfeld, Z., Shapiro, D., Shteinberg, M., Avivi, I., Nahir, M., Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. (2000) Lupus, 9, pp. 401-405 Pasoto, S.G., Mendonca, B.B., Bonfa, E., Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: Clinical, hormonal and therapeutic associations (2002) Lupus, 11, pp. 175-180